CANDEL THERAPEUTICS, INC. Increase (Decrease) in Prepaid Expense and Other Assets
CANDEL THERAPEUTICS, INC. (CADL) reported Increase (Decrease) in Prepaid Expense and Other Assets of $1.07 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-13
- CANDEL THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$192.00K, a 109.91% decline year-over-year.
- CANDEL THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $1.26M.
- CANDEL THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$1.20M.
- CANDEL THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$61.00K, a 124.80% decline year-over-year.
- CANDEL THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2025 was $508.00K.
- CANDEL THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2024 was -$234.00K.
- CANDEL THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$503.00K.
- CANDEL THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2022 was -$416.00K, a 118.82% decline from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$192.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $1.07M 10-Q · filed 2026-08-13 | -$134.00K derived: sum of 3 quarters · filed 2026-08-13 | -$195.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $1.26M 10-Q · filed 2026-05-14 | $58.00K derived: sum of 2 quarters · filed 2026-05-14 | -$3.00K derived: sum of 3 quarters · filed 2026-05-14 | $1.94M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$1.26M derived: sum of 2 quarters · filed 2026-03-12 | $675.00K derived: sum of 3 quarters · filed 2026-08-13 | $508.00K 10-K · filed 2026-03-12 |
| 2025-09-30 | -$61.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $1.88M derived: sum of 2 quarters · filed 2026-08-13 | $1.71M 10-Q · filed 2025-11-13 | $1.33M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $1.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $1.77M 10-Q · filed 2026-08-13 | $1.39M derived: sum of 3 quarters · filed 2026-08-13 | $1.64M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$167.00K 10-Q · filed 2026-05-14 | -$544.00K derived: sum of 2 quarters · filed 2026-05-14 | -$298.00K derived: sum of 3 quarters · filed 2026-05-14 | -$440.00K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$377.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$131.00K derived: sum of 2 quarters · filed 2026-03-12 | -$273.00K derived: sum of 3 quarters · filed 2026-03-12 | -$234.00K 10-K · filed 2026-03-12 |
| 2024-09-30 | $246.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $104.00K derived: sum of 2 quarters · filed 2025-11-13 | $143.00K 10-Q · filed 2025-11-13 | -$590.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$142.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$103.00K 10-Q · filed 2025-08-14 | -$836.00K derived: sum of 3 quarters · filed 2025-08-14 | -$187.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $39.00K 10-Q · filed 2025-05-13 | -$694.00K derived: sum of 2 quarters · filed 2025-05-13 | -$45.00K derived: sum of 3 quarters · filed 2025-05-13 | -$1.19M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$733.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$84.00K derived: sum of 2 quarters · filed 2025-03-13 | -$1.23M derived: sum of 3 quarters · filed 2025-03-13 | -$503.00K 10-K · filed 2025-03-13 |
| 2023-09-30 | $649.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$500.00K derived: sum of 2 quarters · filed 2024-11-14 | $230.00K 10-Q · filed 2024-11-14 | $231.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$1.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$419.00K 10-Q · filed 2024-08-13 | -$418.00K derived: sum of 3 quarters · filed 2024-08-13 | $925.00K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $730.00K 10-Q · filed 2024-05-14 | $731.00K derived: sum of 2 quarters · filed 2024-05-14 | $2.07M derived: sum of 3 quarters · filed 2024-05-14 | $1.29M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $1.34M derived: sum of 2 quarters · filed 2024-03-28 | $563.00K derived: sum of 3 quarters · filed 2024-03-28 | -$416.00K 10-K · filed 2024-03-28 |
| 2022-09-30 | $1.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $562.00K derived: sum of 2 quarters · filed 2023-11-09 | -$417.00K 10-Q · filed 2023-11-09 | -$679.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$781.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$1.76M 10-Q · filed 2023-08-10 | -$2.02M derived: sum of 3 quarters · filed 2023-08-10 | $432.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$979.00K 10-Q · filed 2023-05-11 | -$1.24M derived: sum of 2 quarters · filed 2023-05-11 | $1.21M derived: sum of 3 quarters · filed 2023-05-11 | $1.01M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$262.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $2.19M derived: sum of 2 quarters · filed 2023-03-30 | $1.99M derived: sum of 3 quarters · filed 2023-03-30 | $2.21M 10-K · filed 2023-03-30 |
| 2021-09-30 | $2.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $2.25M derived: sum of 2 quarters · filed 2022-11-10 | $2.47M 10-Q · filed 2022-11-10 | $2.47M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$207.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $18.00K 10-Q · filed 2022-08-05 | $13.00K derived: sum of 3 quarters · filed 2022-08-05 | $40.00K derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-03-31 | $225.00K 10-Q · filed 2022-05-12 | $220.00K derived: sum of 2 quarters · filed 2022-05-12 | $247.00K derived: sum of 3 quarters · filed 2022-05-12 | |
| 2020-12-31 | -$5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $22.00K derived: sum of 2 quarters · filed 2022-03-29 | -$60.00K 10-K · filed 2022-03-29 | |
| 2020-09-30 | $27.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$55.00K 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | -$82.00K 10-Q · filed 2021-09-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |